GENFLEET-B (02595) released its annual performance with a net loss of 1.795 billion yuan, a year-on-year increase of 164.82%.

GENFLEET-B(02595) released its annual performance report for the year ending December 31, 2025, with a revenue of 130 million RMB, an increase of 24.42% year-on-year; research and development costs of 282 million RMB, a decrease of 15.01% year-on-year; and a net loss of 1.795 billion RMB, an increase of 164.82% year-on-year. The company has achieved multiple domestic and international licensing transactions over the years, with steady operating income. In 2025, the annual operating income exceeded 130 million RMB, with a year-on-year increase of nearly 25%. In addition, the company has sufficient cash reserves, with cash and bank balances exceeding 2 billion RMB as of the end of 2025. The company was listed on the Main Board of the Stock Exchange of Hong Kong in 2025. Since 2022, the company has set a record for the highest total amount raised in initial public offerings among all biotechnology companies listed under Chapter 18A of the listing rules (2.68 billion US dollars after exercise of the over-allotment option), and has received the largest cornerstone investment subscription amount (100 million US dollars). The company is also the only company listed under Chapter 18A of the listing rules with a commercialized Category 1 innovative drug and generating licensing revenue at the time of listing. Within six months of listing, the company was included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, and became a component stock of the Hang Seng Index series, including the Hang Seng Composite Index.